| CAS NO: | 132203-70-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 10g | 电议 |
| Molecular Weight (MW) | 492.52 |
|---|---|
| Formula | C27H28N2O7 |
| CAS No. | 132203-70-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 99 mg/mL (201.0 mM) |
| Water: <1 mg/mL | |
| Ethanol: 15 mg/mL (30.5 mM) | |
| Solubility (In vivo) | 5% DMSO+Corn oil: 7 mg/mL |
| Synonyms | FRC-8653; Cilnidipine; Atelec; Cinalong; Siscard; FRC 8653; FRC8653. |
| In Vitro | In vitro activity: Cilnidipine (10 mM) suppresses the elevation of the ratio induced by 40 mM KCl, and this suppression is effectively inhibited after the treatment with omega-conotoxin GVIA. |
|---|---|
| In Vivo | Cilnidipine reduces Ca(2+) influx via N-type Ca(2+) channels after NMDA receptors activation and then protects neurons against ischemia-reperfusion injury in the rat retina in vivo. Cilnidipine significantly prevents the increase in desmin staining and restores the glomerular podocin and nephrin expression compared with amlodipine in spontaneously hypertensive rat/ND mcr-cp (SHR/ND). Cilnidipine also prevents the increase in renal angiotensin II content, the expression and membrane translocation of NADPH oxidase subunits and dihydroethidium staining in SHR/ND. Cilnidipine (30 mg/kg/d as food admix) treatment suppresses the increase in systolic blood pressure in Dahl salt-sensitive rats. Cilnidipine inhibits the increase in blood urea nitrogen and decrease in creatinine clearance as well as progression of glomerular sclerosis. Cilnidipine reduces plasma norepinephrine level and plasma rennin activity compared with vehicle-treated Dahl S rats. Cilnidipine suppresses the pressor response induced by sympathetic nerve stimulation and angiotensin II in pithed rats. Cilnidipine or omega-conotoxin MVIIA decreases mean blood pressure, but slightly increases heart rate in anesthetized rats. Cilnidipine can affect sympathetic N-type Ca(2+) channels in addition to vascular L-type Ca(2+) channels in antihypertensive doses in the rat in vivo. |
| Animal model | Rats |
| Formulation & Dosage | 30 mg/kg/d as food admix |
| References | Hypertens Res. 2003 Sep;26(9):743-7; J Hypertens. 2010 May;28(5):1034-43. |
m.cnreagent.com